Use of s-adenosyl-l-methionine (SAMe) to reverse and/or prevent

Details Use of s-adenosyl-l-methionine (SAMe) to reverse and/or prevent Use of s-adenosyl-l-methionine (SAMe) to reverse and/or prevent

1990-08-31

1992-08-11

Waddell, Frederick E.

Drug, bio-affecting and body treating compositions

Identification or warning feature

Taste or smell or chemical irritation to the eye, nose, or...

514 46, 514922, 5142248, A61K 4900, A61K 3154, A01N 4304

Patent

active

051377128

ABSTRACT:
A method for reversing or preventing the onset of tolerance and the development of extrapyramidal side effects in humans due to prolonged treatment with neuroleptics, comprising including S-adenosyl-L-methionine (SAMe) in the treatment regime. By utilizing SAMe in combination with tolerance-inducing neurolepitcs to maintain a minimum dosage of the drug while retaining its efficacy, the potential for the development of neuroleptic-induced, extrapyramidal side effects is minimized.

REFERENCES:
patent: 4369177 (1983-01-01), Kozaki
Dorris "Effects of . . . " J. Dental Research 69:148, Abst. #313, Mar. 1990.
Goodman The Pharmacological Bases of Therapeutics, pp. 405-407 (1985).
Merck Manual, p. 2488.
Kask Marin, 3'Chase "S-Adenosyl-L-Methionine . . . " Soc. Nurosci Abstr. 15(1): 268 (1989).
Costall et al., (1973) Arzneim.-Forsch. (Drug Res.) 5:674-683.
Janssen et al., (1965) Arzneim.-Forsch. (Drug Res.), 15:104-117.
Seeman et al., (1976), Nature, 6:717-719.
Rupniak et al., (1983) Life Sciences 32:2289-2311.
Creese et al., (1976) Science 192:481-483.
S. Snyder, (1988) Neuropsychopharmacology, 11:197-199.
A. Carlsson, (1988) Neuropsychopharmacology, 1:179-186.
Richelson et al., (1984), European Journal of Pharmacology, 103:197-204.
D. Pickar, (1988), Schizophrenia Bulletin 14(2):255-267.
Oates et al., (1991) The New England Journal of Medicine, vol. 324, No. 11:746-754.
Crews et al., (1983) Psychopharmacology 81:208-213.
Crews (1982) Psychopharmacology Bulletin 18:135-143.
Hirata et al. (1979) Cell Biology 76:368-372.
Owen et al. (1980) Life Sciences 26:55-59.
Baldessarini, M.D. (1987) The American Journal of Medicine 83 (Suppl. 5A):95-103.
Gerlach et al. (1988) Acta Psychiatr. Scand. 77:369-378.
Devanand et al. (1989) Arch. Neurol. 46:854-857.
Steardo et al. (1985) Journal of Neurochemistry 45:784-790.
Loesberg et al. (1989) Life Sciences 45:1227-1235.
Sakamoto et al. (1989) Eur. J. Immunol. 19:873-879.
Briley et al. (1978) European Journal of Pharmacology 50:283-284.
Parashos et al. (1989) Neurosciences Letter 105.
Le Fur et al. (1983) Life Sciences 32:2321-2328.
Hirata et al. (1980) Science 209:1082-1090.
Bhargava (1984) Neuropharmacology 23:439-444.
Cohen et al. (1988) J. Clin. Psychopharmacol. 8:43-47.
Kleinman et al. (1988) Schizophrenia Bulletin 14:209-216.
Cimino et al. (1984) Life Sciences 34:2029-2039.
Sarda et al. (1989) Dev. Pharmacol Ther. 13:104-112.
Seeman (1988) Journal of Clinical Psychopharmacology, vol. 8, No. 4, pp. 3S-9S.
Hershkowitz et al. (1982) in Progress Brian Research, Gispen et al., eds., 56:419-434.
Carney (1986) Clinical Neuropharmacology 9:235-243.
Lieberman et al. (1988) Journal of Clinical Psychopharmacology.

Affiliated with

Also associated with

Rating

Use of s-adenosyl-l-methionine (SAMe) to reverse and/or prevent does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of s-adenosyl-l-methionine (SAMe) to reverse and/or prevent , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of s-adenosyl-l-methionine (SAMe) to reverse and/or prevent will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-345102